News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics to Announce First Quarter 2017 Financial Results on May 4, 2017
STAMFORD, Conn. , April 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845
- I.V. CR845 statistically equivalent to placebo across all measures of respiratory safety -
View HTML
Toggle Summary Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
STAMFORD, Conn. , April 05, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
STAMFORD, Conn. , March 30, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Proposed Offering of Common Stock
STAMFORD, Conn. , March 29, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics to Webcast Presentation at the 16th Annual Needham Healthcare Conference
STAMFORD, Conn. , March 28, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
Met primary endpoint with 68% reduction in worst itching scores versus placebo after eight-week treatment period (p < 0.0019)                        Met secondary endpoint in quality of life domains versus placebo after eight-week  treatment period (p < 0.0007)     I.V.
View HTML
Toggle Summary Cara Therapeutics to Present at March Medical Meetings
STAMFORD, Conn. , March 13, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
- Conference call today at 4:30 p.m. ET -
View HTML
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017
STAMFORD, Conn. , March 02, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML